Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 855 results for position

  1. Adults with Von Hippel-Lindau disease to benefit from new treatment

    NICE has recommended belzutifan for some adults with Von Hippel-Lindau disease, in final draft guidance, which could benefit up to 100 people.

  2. Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over (TA1003)

    Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for transfusion-dependent beta-thalassaemia in people 12 years and over.

  3. Emergency kits for people with adrenal insufficiency recommended to avoid hospital admission

    People with adrenal insufficiency should be given an emergency medical kit with potentially life-saving steroid injections, according to our new clinical guideline.

  4. Benefits of new Alzheimer's treatment lecanemab are too small to justify the cost to the NHS

    Our draft recommendation follows analysis of clinical trial evidence and reviewing the benefits of slowing disease progression, with the cost of treatment.

  5. Caval valve implantation for tricuspid regurgitation (IPG791)

    Evidence-based recommendations on caval valve implantation for tricuspid regurgitation in adults. This involves implanting valves into 1 or both caval veins without disturbing the tricuspid valve.

  6. No evidence to support the price variation in heart valves used by the NHS

    Draft guidance issued today (9 August) states that the variation in price the NHS is paying for valves used in keyhole heart procedures is not supported by reliable evidence.

  7. Linzagolix for treating moderate to severe symptoms of uterine fibroids (TA996)

    Evidence-based recommendations on linzagolix (Yselty) for treating moderate to severe symptoms of fibroids in adults of reproductive age.

  8. Thousands could benefit from new option for treating symptoms of uterine fibroids

    As many as 30,000 adults could benefit from a new treatment for moderate to severe symptoms of uterine fibroids after we published final guidance today (14 August 2024) recommending linzagolix.

  9. Two new treatment options for incurable blood cancer assessed

    We’ve recommended 2 new treatments for multiple myeloma, an incurable blood cancer that affects bone marrow, in draft guidance issued for public consultation.

  10. World's first gene editing therapy for blood disorder to be available to hundreds of patients in England

    Patients in England with severe beta-thalassaemia will be amongst the first in Europe to benefit from one-time gene therapy exagamglogene autotemcel.

  11. 14,000 women at risk of fractures after the menopause to benefit from bone disease drug

    Over 14,000 people to benefit after NICE published final guidance recommending abaloparatide as an option for treating osteoporosis after menopause, if there is a very high risk of fracture.

  12. Anaphylaxis (QS119)

    This quality standard covers care after emergency treatment for suspected anaphylaxis, including assessment and referral to specialist allergy services. It describes high-quality care in priority areas for improvement.

  13. How NICE is ensuring its topic prioritisation decisions are grounded in lived experience

    Simon Denegri discusses NICE’s commitment to involving the public voice in its work and decisions.

  14. Introducing a new way of prioritising our guidance topics

    NICE's deputy chief executive, Jonathan Benger, talks about our new approach to prioritisation.

  15. Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (TA992)

    Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for HER2-low metastatic or unresectable breast cancer after chemotherapy in adults.